Funder
Medical University of Vienna
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference33 articles.
1. Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother. 2011;66:iii11–8. https://doi.org/10.1093/jac/dkr095.
2. AstraZeneca. 2019. Zinforo (powder for concentrate for solution for infusion): summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/zinforo-epar-product-information_en.pdf. Accessed 8 Oct 2023.
3. Allergan Inc. 2019. Teflaro® (ceftaroline fosamil) for injection, for intravenous use: prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/200327s022lbl.pdf. Accessed 8 Oct 2023.
4. Casapao AM, Davis SL, Barr VO, et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58:2541–6. https://doi.org/10.1128/AAC.02371-13.
5. Dryden M, Zhang Y, Wilson D, et al. A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities. J Antimicrob Chemother. 2016;71:3575–84. https://doi.org/10.1093/jac/dkw333.